Regulatory
Is Compounded Tirzepatide FDA Approved?
No. Compounded tirzepatide is not FDA approved. The FDA does not review compounded preparations for safety, effectiveness, or quality before they are sold. Claims that a pharmacy is 'FDA registered' or 'FDA inspected' describe facility oversight, which is a different thing from approval of the product you receive.
Key takeaways
- Compounded tirzepatide is not FDA approved — no exceptions and no qualified versions of this answer.
- The FDA does not review compounded preparations before sale for safety, effectiveness, or quality.
- 'FDA registered' describes a facility registration, not product approval.
- 'FDA inspected' means a facility was inspected, which is not the same as a product being approved.
- Marketing that blurs these terms is the single most common misrepresentation in this market.
| Is compounded tirzepatide FDA approved? | No |
|---|---|
| Pre-market FDA review of the product | None |
| FDA registration of a 503B facility | Facility oversight, not product approval |
| State board licensure | Pharmacy licensure, not product approval |
| What approval would require | A marketing application reviewed and granted by the FDA |
What do 'FDA registered' and 'FDA approved' actually mean?
Registration means a facility has told the FDA it exists and operates in a particular category — a 503B outsourcing facility registers with the FDA and is subject to inspection. Approval means the agency has reviewed a specific product's evidence and authorised its marketing.
One is an administrative status of a building and its operator. The other is a regulatory judgement about a product. Marketing frequently uses the first to imply the second.
Does inspection mean the product is verified?
No. An inspection assesses whether a facility meets applicable standards at the time of inspection. It does not test the specific vial you receive, verify its concentration, or evaluate the preparation's effectiveness. A facility can be inspected and still produce a preparation whose performance nobody has measured — because nobody has measured any compounded preparation's performance in a randomised trial.
Why is this distinction worth this much attention?
Because it is the specific claim that leads people to believe they are buying an equivalent product at a discount. Everything else in the compounded conversation — cost, access, pharmacy quality — can be weighed sensibly once this is clear, and cannot be weighed sensibly while it is confused.
A provider using 'FDA registered' prominently in consumer marketing is worth more scepticism, not less.
- Treat 'FDA registered' as a statement about a facility, not a product.
- Treat 'FDA inspected' the same way.
- Ask directly: 'Is this product FDA approved?' The honest answer is no.
- Ask what is verified instead: pharmacy licence, facility type, concentration, beyond-use date.
What the evidence shows
- That compounded preparations are not FDA approved.
- That facility registration and inspection are distinct from product approval.
What the evidence does not show
- That registration or inspection implies product verification.
- That any compounded tirzepatide product has been approved anywhere.
Related: 503A versus 503B · Pharmacy red flags
What exactly differs between approved and compounded tirzepatide?
| Attribute | FDA-approved (Zepbound / Mounjaro) | Compounded tirzepatide |
|---|---|---|
| Premarket FDA review | Yes — safety, efficacy, and quality reviewed | No |
| Randomised trial evidence | SURMOUNT and SURPASS programmes | None identified |
| Concentration | Fixed and verified by the manufacturer | Varies by pharmacy; not independently verified |
| Presentation | Fixed-dose pen or autoinjector | Commonly a vial requiring measurement |
| Dating | Manufacturer expiry from stability testing | Pharmacy-assigned beyond-use date |
| Adverse-event capture | Systematic post-marketing surveillance | Less systematic |
| Consumer verification route | FDA approval record | State board licence lookup |
| Group | FDA-approved | Compounded |
|---|---|---|
| Randomised trials | 6 | 0 |
| Verified concentration | 1 | 0 |
| Premarket review | 1 | 0 |
What is the regulatory timeline for compounded tirzepatide?
The compounding of tirzepatide was permitted only because the drug appeared on the FDA drug shortage list. Once the shortage was resolved, the legal basis for compounding an essentially-a-copy version ended. The sequence below is the documented chain of that change, each step verifiable against the sources listed at the foot of this page.
| Date | Event |
|---|---|
| 2022 | Tirzepatide added to the FDA drug shortage list amid surging demand. |
| 2024-10-02 | FDA removes tirzepatide from the drug shortage list, determining supply can meet national demand. |
| 2024-10-11 | Court remands the decision to the FDA for reevaluation after the Outsourcing Facilities Association and FarmaKeio sue. |
| 2024-12-19 | FDA issues a declaratory order reaffirming the tirzepatide shortage is resolved, with grace periods for compounders. |
| 2025-02-18 | Enforcement discretion ends for 503A state-licensed pharmacies compounding tirzepatide injection. |
| 2025-03-19 | Enforcement discretion ends for 503B outsourcing facilities compounding tirzepatide injection. |
| 2025-05 | US District Court for the Northern District of Texas upholds the FDA's shortage resolution. |
| 2026-02-06 | FDA announces steps to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved products. |
| Product | Regulatory status | What that means for availability |
|---|---|---|
| Zepbound (tirzepatide) | FDA approved for chronic weight management | Available by prescription through normal pharmacy channels |
| Mounjaro (tirzepatide) | FDA approved for type 2 diabetes | Available by prescription through normal pharmacy channels |
| Compounded tirzepatide injection | Not FDA approved; shortage resolved, enforcement discretion ended | Routine compounding no longer permitted as an essentially-a-copy product |
| Compounded oral, sublingual, ODT or troche tirzepatide | Not FDA approved in any form | Never covered by shortage-era compounding; no approved oral tirzepatide product exists |
| Research-grade or grey-market tirzepatide | Not a medicine; outside the regulated supply chain | No pharmacy accountability, no verified identity, purity, or sterility |
What does this mean if you are buying or already using compounded tirzepatide?
The practical consequences differ depending on whether you are considering starting, already receiving a compounded product, or comparing prices. None of the following is legal advice, and none of it is a reason to stop a prescribed medicine without speaking to the prescriber who issued it.
- Compounded tirzepatide marketed as an equivalent of Zepbound or Mounjaro is generally no longer permitted.
- Some sellers continue to market 'personalised' compounded tirzepatide by adding ingredients such as vitamin B12 or altering the dose. The FDA treats products within a narrow range of the approved dose as essentially copies.
- Any seller still advertising compounded tirzepatide should be treated as a significant verification question, not a bargain.
- Oral, sublingual, ODT, and troche tirzepatide have never been FDA approved in any form and were never covered by shortage-era compounding.
- Patients previously using compounded tirzepatide should discuss transition to an approved product with a prescriber.
The most useful single question to ask any seller still advertising compounded tirzepatide is what legal basis it is operating under, and which state-licensed pharmacy is dispensing. A seller that cannot answer both clearly is not a seller whose product can be verified.
What does the regulatory framework actually say?
Compounding occupies a specific legal position that is frequently described inaccurately in marketing. A 503A pharmacy prepares patient-specific preparations against individual prescriptions and is licensed by a state board of pharmacy. A 503B outsourcing facility may prepare larger batches without individual prescriptions, registers with the FDA, and is subject to current good manufacturing practice requirements. Neither route produces an FDA-approved product.
That last sentence is the one most often blurred. Registration is not approval. Inspection is not approval. Operating legally is not approval. Approval is a specific determination that the FDA has reviewed evidence of safety, effectiveness, and manufacturing quality for a particular product before it is marketed, and no compounded preparation has been through that process.
| Term | What it actually means | What it does not mean |
|---|---|---|
| FDA approved | The agency reviewed safety, efficacy and quality evidence before marketing | Applies to any compounded preparation |
| FDA registered | The facility filed a registration with the agency | The product was reviewed or approved |
| FDA inspected | The agency conducted a facility inspection | The product was approved, or that the inspection found no problems |
| State licensed | A state board authorised the pharmacy to operate | Any federal review of the product |
| cGMP compliant | The facility follows manufacturing practice standards | The specific product was evaluated for safety or efficacy |
| Third-party tested | A laboratory analysed a sample | Systematic batch verification, unless the scope and frequency are disclosed |
What can a patient actually verify before paying?
Where randomised evidence is absent, verification of the supply chain takes its place as the meaningful check. The useful feature of these checks is that they are all things a reader can do independently, against public records, before any money changes hands.
| Check | How to do it | What a refusal or gap tells you |
|---|---|---|
| Pharmacy legal name | Ask the provider in writing before enrolling | A provider unwilling to name its pharmacy is withholding the single most useful fact |
| State licence | Search the licensing state board's public register | An unlisted or lapsed licence is disqualifying |
| 503A or 503B status | Ask, then check the FDA outsourcing facility register for 503B claims | A 503B claim absent from the register is a serious discrepancy |
| Disciplinary history | State board records and enforcement notices | Prior action is not automatically disqualifying but is material |
| Concentration in mg/mL | Ask before ordering; confirm on the dispensing label | An unwillingness to state concentration makes safe use impossible |
| Beyond-use date policy | Ask what date is assigned and on what basis | No stated policy suggests weak quality systems |
| Cold-chain and excursion policy | Ask who bears risk if a shipment arrives warm | No policy means the risk sits with you |
A provider that answers all seven readily has demonstrated something meaningful. One that treats these as intrusive has also answered, in a different way. This is not a guarantee of quality — it is the strongest signal available to a consumer in a market where the usual guarantee, regulatory approval, does not exist.
What are the limits of what this page can tell you?
This page describes a regulatory framework and a verification method. Both have limits that matter.
- Regulatory status changes, and enforcement priorities change with it. Statements here carry the verification date shown above.
- State licensing requirements differ, so a check that is straightforward in one state may be harder in another.
- Verification of a pharmacy's licence establishes that it is authorised to operate. It does not establish the quality of any particular preparation.
- No verification step available to a consumer substitutes for the premarket review that approved products undergo.
What does this page cover, and what does it deliberately leave out?
This page addresses Product approval versus facility status and consumer checks, organised around the primary question of is compounded tirzepatide FDA approved. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Product approval versus facility status and consumer checks | Covered on this page | Regulatory or policy source |
| Individualized clinical instruction | Deliberately not covered | Belongs with the dispensing pharmacy and your prescriber |
What are the limits of what this page can tell you?
Every page on this site rests on a specific regulatory position on compounded preparations, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the dispensing pharmacy and your prescriber.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
The following would trigger a revision to this page, recorded in its change history:
- New primary evidence bearing directly on is compounded tirzepatide FDA approved.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 6 technical terms this page uses, including 503A, 503B, GLP-1, beyond-use date — in the specific sense used above.
| 503A | A pharmacy that compounds patient-specific preparations against individual prescriptions. It is licensed by a state board of pharmacy and is not subject to the same federal manufacturing requirements as a 503B facility. |
|---|---|
| 503B | An outsourcing facility that may compound in larger batches without individual prescriptions. It registers with the FDA and is subject to current good manufacturing practice requirements, though registration is still not product approval. |
| GLP-1 | Glucagon-like peptide-1. An incretin hormone that slows gastric emptying, signals satiety to the brain, stimulates glucose-dependent insulin release, and suppresses inappropriate glucagon secretion. |
| beyond-use date | The date after which a compounded preparation should not be used. It is assigned by the compounding pharmacy based on its own conditions, and is typically much shorter than a manufacturer expiry date derived from formal stability testing. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| mg/mL | Milligrams of drug per millilitre of liquid — the concentration. Two vials containing the same nominal dose can require different injection volumes if their concentrations differ, which is why this site does not publish volume calculations. |
Frequently asked questions
Is compounded tirzepatide FDA approved?
No.
What does 'FDA registered pharmacy' mean?
That the facility has registered with the FDA in a defined category. It is not product approval.
Does FDA inspection verify the product?
No. Inspection assesses a facility against standards; it does not test the vial you receive.
Is any compounded tirzepatide approved anywhere?
Compounded preparations are not approved products by definition.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.